• Search History (Register)
  • MeSH Browser
  • [Clear]
    • Canada

Welcome to the international HTA database


Showing [3358 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Misoprostol administration for the treatment of post-partum uterine atony: clinical effectiveness, safety, and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Bladder instillation of gentamicin for the treatment of recurrent urinary tract infections: clinical evidence and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Routine blood tests for patients in the intensive care unit: clinical effectiveness, cost-effectiveness, and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Swabbing techniques for the detection of bacterial colonization in wounds: comparative clinical evidence and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Long term Use of Clopidogrel for Patients with Stents or Acute Coronary Syndrome: A Review of Clinical and Cost-effectiveness and Guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Management of diabetes in the long-term care population: a review of guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Long term use of clopidogrel for patients with stents or acute coronary syndrome: a review of clinical and cost-effectiveness and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Vaginal preparation prior to cesarean delivery: clinical evidence
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Photo-activated disinfection therapy for non-dental surgery: review of the clinical effectiveness
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Azilsartan Medoxomil + Chlorthalidone (Edarbyclor- Takeda Canada Inc.) indication: severe hypertension
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Hemolysis and blood infusion pumps for patients receiving blood or blood components: standards and evidence-based guidelines: standards and evidence-based guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Technologies assisting in remote consultations for the diagnosis of stroke: a review of the clinical evidence
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Bariatric surgery for obese patients with co-morbidities: a review of clinical effectiveness, cost-effectiveness, and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Appropriateness of CT imaging to support the diagnosis of stroke: a review of the clinical evidence
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) O-Arm technology in spinal, neurological, orthopedic, or trauma surgery settings: clinical effectiveness and benefits and harms to patients and hospital staff
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Linagliptin-metformin (Jentadueto - Boehringer Ingelheim (Canada) Ltd.) indication: type 2 diabetes mellitus
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Intraoperative monitoring during spinal or neurological surgeries: clinical effectiveness and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Perampanel (Fycompa - Eisai Ltd.) indication: epilepsy, partial-onset seizures
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Indigenous knowledge for mental illness and chronic disease: clinical effectiveness and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Azilsartan Medoxomil (Edarbi - Takeda Canada Inc.) indication: mild to moderate essential hypertension
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Management of coronary artery disease in primary and community care: guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Distance consultation for chronic, non-healing, lower extremity wounds: clinical evidence
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Heating standards for magnetic resonance conditional medical devices: clinical evidence
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Plasma vaporization for the treatment of benign prostatic hypertrophy: clinical and cost-effectiveness, and safety
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Screening tools compared to parental concern for identifying speech and language delays in preschool children: a review of the diagnostic accuracy
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Use of surgical masks in the operating room: a review of the clinical effectiveness and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) GreenLight laser for the treatment of benign prostatic hypertrophy: clinical and cost-effectiveness, and safety
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Cleansing of the cervix prior to hysterosalpingogram: clinical evidence and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Community-based programs to improve early childhood health outcomes: guidelines and recommendations
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) CPAP treatment for adults with obstructive sleep apnea: review of the clinical and cost-effectiveness and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Non-steroidal anti-inflammatory drugs for pain: comparative clinical and cost-effectiveness
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Dressing materials for the treatment of pressure ulcers in patients in long-term care facilities: a review of the comparative clinical effectiveness and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Management of chronic obstructive pulmonary disease in primary and community care: guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Suboxone versus methadone for the treatment of opioid dependence: a review of the clinical and cost-effectiveness
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Comparison of the Ankle Brachial Pressure Index (ABI) doppler with the pocket doppler with plethysmography probe in the assessment of arterial disease in diabetic patients: clinical and cost-effectiveness
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Optimal in-hospital umbilical cord care for newborns: clinical evidence and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Medication administration via metered dose inhalers and aerochambers versus nebulizers for adult patients: clinical effectiveness
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Extracorporeal circuit for patients undergoing hemodialysis: safety
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Group care for chronic disease management: a review of the clinical effectiveness, cost-effectiveness, and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Peripherally inserted central catheter-associated mast cell activation syndrome: clinical evidence
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Needle or open fasciotomy for dupuytren
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Mold prevention for hospital bed mattresses: clinical effectiveness and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Medication assessment alerts for in-hospital medication management: clinical evidence and guidelines
2013     Institute of Health Economics (IHE) Total prosthetic replacement of the temporomandibular joint: a rapid evidence assessment and economic analysis
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Supraglottic airway devices in out-of-hospital settings: clinical evidence and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Peer support for diabetes, heart disease and HIV/AIDS: a review of the clinical effectiveness, cost-effectiveness, and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Pediatric stretchers and stretcher cribs: safety and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Pain neurophysiology education for the management of persistent pain: clinical evidence and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) The use of restraints during acute mental health interventions: a review of the clinical evidence and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Negative pressure wound therapy for the management of high risk surgical incisions or high risk patients: clinical effectiveness, cost-effectiveness, and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Updated reports and recommendations on second- and third-line therapies for type 2 diabetes
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Multi-dose contrast media for patients undergoing computed tomography: clinical benefits, harms, and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Cefazolin for preoperative prophylaxis in overweight adults having any type of surgery: clinical effectiveness and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Follow-up imaging for simple adnexal cysts: clinical evidence, cost-effectiveness and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Indigenous knowledge for smoking cessation: benefits and effectiveness
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Ultrasound versus computed tomography for children with suspected appendicitis: clinical evidence, cost-effectiveness, and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Screening and diagnostic tools for autism spectrum disorder in children: a review of guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Delivery of podiatry care for adults with diabetes or chronic foot conditions: a review of the clinical effectiveness
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness and safety
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) X-ray series for foot and ankle injuries: clinical evidence, cost-effectiveness, and guidelines
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Assessment of the PARLER (Programme d'Accès Rapide Lavallois en Rhumatologie) program]
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Counselling or psychotherapy interventions for patients with a history of sexual or physical assault: patient benefits, harms, and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Adjuvant and neoadjuvant chemotherapy and radiation for the treatment of rectal cancer: economic evidence
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Automation for the preparation of intravenous solutions for acute care patients: cost-effectiveness and safety
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Optimal screening procedures prior to physician visits: guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Sexual Assault Nurse Evaluation (SANE) rape crisis procedure: clinical effectiveness and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Anaphylaxis in seniors eeceiving intravenous antibiotics in long-term care: clinical evidence and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Dornase alfa for patients with cystic fibrosis: a review of the clinical efficacy and cost-effectiveness
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Oral lidocaine for reflux or mucositis: clinical evidence and guidelines
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [The efficacy of rehabilitative interventions and pharmacological treatments for children aged 2 to 12 years with autism spectrum disorder (ASD)]
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Total contact casts for diabetic foot ulcers: cost-effectiveness
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Prevention and management of violence in long-term care: clinical evidence and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Point of care testing for human chorionic gonadotropin, creatinine, and blood urea nitrogen: cost-effectiveness
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) High-sensitivity cardiac troponin for the rapid diagnosis of acute coronary syndrome in the emergency department
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Tranexamic acid for the management of bleeding: a review of the clinical effectiveness and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Components and materials used for total hip replacement: a review of the comparative clinical effectiveness
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Endovascular therapy for elective and ruptured abdominal aortic aneurysm procedures: a description of utilization trends across Canada
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Knee implant systems: a review of the comparative clinical effectiveness
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Codeine and acetylsalicylic acid for the management of post-tonsillectomy or adenoidectomy pain: a review of the clinical evidence
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Intramuscular oxytocin for the prevention of post-partum hemorrhage outside the hospital: clinical evidence and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Antimicrobial ointments for patients undergoing hemodialysis: a review of evidence-based guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Warming of amniofluid: safety
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Advisability of expanding the Québec newborn blood screening program]
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Single-use versus single patient-use electric breast pump kits for the prevention of hospital-acquired infections in mothers and newborns: comparative safety
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Point of care testing compared to laboratory testing for the assessment of white blood cell counts and differentials: a review of the clinical effectiveness, diagnostic precision and accuracy, cost-effectiveness, and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Management of childbirth by midwives: clinical evidence and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Frequency of blood pressure measurements for children and adults: evidence-based guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) External devices for cervical spine immobilization in the pre-hospital setting: clinical effectiveness
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Removal of intravenous lines following outpatient day procedures: guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Ferumoxytol versus other intravenous iron therapies for anemia: a review of the clinical and cost-effectiveness and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Intravenous ketamine for the treatment of pain syndromes: clinical effectiveness
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Nabilone for chronic pain: clinical effectiveness, safety, and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Nabilone for nausea or vomiting not related to chemotherapy: clinical effectiveness and safety
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Portable bone mineral density scanners for screening and diagnosis of osteoporosis: uses, limitations, and guidelines
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Use of medullary neurostimulators for the treatment of chronic non-cancer pain]
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) The prevention of blood-borne infection transmission during immunization: clinical evidence and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) The use of spine boards in the pre-hospital setting for the stabilization of patients following trauma: a review of the clinical evidence and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) The emotional freedom technique for the treatment of post-traumatic stress disorder, depression, or anxiety: clinical evidence
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Pentazocine versus short-acting opioids for chronic or acute pain: a review of the clinical effectiveness
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Protease inhibitor use for chronic hepatitis C infection in prior null responders and recurrent hepatitis C infection post liver transplant: a review of the clinical evidence